The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice - PubMed (original) (raw)
The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice
B Van den Eynde et al. J Exp Med. 1991.
Abstract
We showed previously that mouse mastocytoma P815 expresses several distinct antigens that are recognized by cytolytic T lymphocytes (CTL) of syngeneic DBA/2 mice. Antigens P815A and P815B are usually lost jointly and are targets for immune rejection responses in vivo. We used a cosmid library and a CTL stimulation assay to obtain transfectants expressing tumor rejection antigen P815A. From these transfectants we retrieved gene P1A which transferred the expression of both P815A and B. This gene is unrelated to three previously isolated genes coding for tum-antigens. It encodes a putative protein of 224 amino acids which contains two highly acidic domains showing homology with similar regions of nuclear proteins. The P1A gene expressed by tumor P815 is completely identical to the gene present in normal DBA/2 cells. Expression of the gene was tested by Northern blots. Cells from liver, spleen, and a number of mast cell lines were negative, but mast cell line L138.8A produced a high level of P1A message and was lysed by CTL directed against antigens P815A and B. We conclude that major tumor rejection antigens of P815 are encoded by a gene showing little or no expression in most normal cells of adult mice.
Similar articles
- Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide.
Lethé B, van den Eynde B, van Pel A, Corradin G, Boon T. Lethé B, et al. Eur J Immunol. 1992 Sep;22(9):2283-8. doi: 10.1002/eji.1830220916. Eur J Immunol. 1992. PMID: 1381312 - Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A.
Warnier G, Duffour MT, Uyttenhove C, Gajewski TF, Lurquin C, Haddada H, Perricaudet M, Boon T. Warnier G, et al. Int J Cancer. 1996 Jul 17;67(2):303-10. doi: 10.1002/(SICI)1097-0215(19960717)67:2<303::AID-IJC24>3.0.CO;2-A. Int J Cancer. 1996. PMID: 8760603 - Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
Boon T, Coulie P, Marchand M, Weynants P, Wölfel T, Brichard V. Boon T, et al. Important Adv Oncol. 1994:53-69. Important Adv Oncol. 1994. PMID: 8206495 Review. No abstract available. - Protein tumor antigens.
Srivastava PK. Srivastava PK. Curr Opin Immunol. 1991 Oct;3(5):654-8. doi: 10.1016/0952-7915(91)90092-f. Curr Opin Immunol. 1991. PMID: 1755984 Review.
Cited by
- What do cancer-specific T cells 'see'?
Shah S, Al-Omari A, Cook KW, Paston SJ, Durrant LG, Brentville VA. Shah S, et al. Discov Immunol. 2022 Dec 6;2(1):kyac011. doi: 10.1093/discim/kyac011. eCollection 2023. Discov Immunol. 2022. PMID: 38567060 Free PMC article. Review. - Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J, Chan HF, Noblecourt L, Ramirez-Valdez RA, Pereira-Almeida V, Zhou Y, Pollock E, Cappuccini F, Redchenko I, Hill AV, Leung CSK, Van den Eynde BJ. McAuliffe J, et al. J Immunother Cancer. 2021 Sep;9(9):e003218. doi: 10.1136/jitc-2021-003218. J Immunother Cancer. 2021. PMID: 34479921 Free PMC article. - The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.
Shukla A, Cloutier M, Appiya Santharam M, Ramanathan S, Ilangumaran S. Shukla A, et al. Int J Mol Sci. 2021 Feb 17;22(4):1964. doi: 10.3390/ijms22041964. Int J Mol Sci. 2021. PMID: 33671123 Free PMC article. Review. - Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.
Zhu J, Powis de Tenbossche CG, Cané S, Colau D, van Baren N, Lurquin C, Schmitt-Verhulst AM, Liljeström P, Uyttenhove C, Van den Eynde BJ. Zhu J, et al. Nat Commun. 2017 Nov 10;8(1):1404. doi: 10.1038/s41467-017-00784-1. Nat Commun. 2017. PMID: 29123081 Free PMC article. - Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ, Charo J, Fabrizio D, Goldberg ME, Albacker LA, Pao W, Chmielecki J. Hartmaier RJ, et al. Genome Med. 2017 Feb 24;9(1):16. doi: 10.1186/s13073-017-0408-2. Genome Med. 2017. PMID: 28231819 Free PMC article.
References
- Cancer Res. 1960 Dec;20:1561-72 - PubMed
- EMBO J. 1983;2(2):245-54 - PubMed
- Annu Rev Cell Biol. 1986;2:367-90 - PubMed
- Exp Cell Res. 1985 May;158(1):237-43 - PubMed
- Cancer Res. 1988 Jun 1;48(11):2975-80 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases